



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉dmrc@esic.nic.in

U-25/12/142C-146C/Amendment/Site/2022-MedV (e-85591)

To
Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

(संशोधन / Amendment -86)

Sub: Amendment in Change in Manufacturing Site address of M/s. Eli Lilly Company (India) Pvt. Ltd., for the product Item no. 1691 in RC-145C and Item no.1770 in RC-157 -reg

Ref.: U-25/12/142C-146C/2019-Med.V (RC-145C) dt. 14.10.2021, extended upto 30.04.2025
U-25/12/ExemptionunderPublicProcurement(MII)Order/2022-Med.V(E-101005) Dt: 10.06.2024
effective w.e.f. 10.06.2024 to 09.06.2026

Sir/Madam,

The following amendment may please be noted:

RC No	Item No.	Item Name	Existing Mfg. Site	New Manufacturing Site Amendment
145C	1691	Insulin Inj.- Each cartridge to contain: 25% Lispro and 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] 3ml Cartridge (Brand: Humalog Mix 25)	M/s Eli Lilly Italia S.P.A., Via Gramsci 731-733, Sesto Fiorentino - Firenze, Italy 50019	M/s. Lilly France SAS, Centre de Production 2, Rue Du Colonel Lilly, Zone Industrielle, F-67640 Fegersheim, France
157	1770	Insulin Lispro Inj.- Each Cartridge contain: Insulin Lispro (100IU/ml), [Monocomponent Insulin, recombinant DNA Origin] 3ml Cartridge (Brand Name: Humalog).		

1. The said amendment has been issued on the request of the firm **M/s. Eli Lilly Company (India) Pvt. Ltd.**

2. The drug(s) supplies by M/s. Eli Lilly Company (India) Pvt. Ltd. shall continue to adhere to composition, strength, standards and packing as approved under the respective DGEISIC Rate Contract(s) & conform to the standards and specifications as per the Drug & Cosmetic Act and any amendments thereof.

3. M/s. Eli Lilly Company (India) Pvt. Ltd. shall continue to be governed by the Terms & Conditions of respective DGEISIC Rate Contract(s).

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Neeta Garbiyal
Date: 18-03-2025
14:07:53
डॉ. चिकित्सा आयुक्त (दर संविदा)

Copy for information to:

1. M/s. Eli Lilly Company (India) Pvt. Ltd. Plot no.92, Sector-32, Gurgaon-122001 Haryana (email: singh_inderpal@lilly.com)
2. Content Manager with request for uploading on ESIC website.
3. Guard file / Spare